Voorbeelden van het gebruik van Eviplera in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
How is Eviplera used?
Eviplera may affect your kidneys.
What is Eviplera used for?
Other information about Eviplera.
How has Eviplera been studied?
Do not breast-feed during treatment with Eviplera.
Why has Eviplera been approved?
Interaction not studied with any components of Eviplera.
Eviplera outer packaging only.
What benefit has Eviplera shown during the studies?
Eviplera must be taken with food see section 5.2.
Recommendation concerning co-administration with Eviplera.
What Eviplera looks like and contents of the pack?
Interaction not studied with any of the components of Eviplera.
Eviplera may interact with other medicines.
These symptoms resolved after Eviplera was discontinued.
Eviplera contains lactose
It is recommended that Eviplera be swallowed whole with water.
Eviplera Conditions or restrictions regarding supply and use.
It is not recommended to co-administer Eviplera with other NNRTIs.
Co-administration of Eviplera and didanosine is not recommended see section 4.4.
Patients who have HIV and hepatitis B may see a worsening of their liver problems when stopping Eviplera.
Eviplera must be administered with food to ensure optimal absorption see section 4.2.
If a patient vomits within 4 hours of taking Eviplera another Eviplera tablet should be taken with food.
Eviplera should be used with caution when co-administered with medicinal products with a known risk of Torsade de Pointes.
As soon as serious skin and/or mucosal reactions are observed, Eviplera must be discontinued
Discontinuation of Eviplera therapy in patients co-infected with HIV
it is especially important not to stop your Eviplera treatment without talking to your doctor first.
Discontinuation of Eviplera therapy in patients co-infected with HIV
In study GS-US-264-0106, 4 of the 469 patients who switched from a ritonavir-boosted protease inhibitor-based regimen to Eviplera had HIV-1 with reduced susceptibility to at least one component of Eviplera through week 48.